Recursion Pharmaceuticals, Inc. RXRX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s change in accrued liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported change in accrued liabilities of -$18.45M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s change in accrued liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s change in accrued liabilities increased by 30.6% year-over-year, from -$26.59M to -$18.45M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.